Annual Report for the financial year ended March 31, 2026

Corporate Office: Solara Active Pharma Sciences Limited TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in Website: www.solara.co.in Date: August 25, 2026 The BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 541540, 890202 Symbol: SOLARA, SOLARAPP1 Dear Sir / Madam, Subject: Notice of Ninth Annual General Meeting and Annual Report for the financial year 2025-26 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Notice convening Ninth Annual General Meeting (AGM) along with the Annual Report for the financial year 2025-26 which will be circulated to the shareholders through electronic mode. The Ninth AGM is scheduled to be held on Friday, September 18, 2026, at 10.30 A.M (IST) through Video Conference (VC) / Other Audio-Visual Means (OAVM), in accordance with the Circulars issued by Ministry of Corporate Affairs (MCA), SEBI and applicable provisions of the Companies Act, 2013 and the Rules made thereunder. The Notice along with the Annual Report for the financial year 2025-26 made available on the Company's website at https://solara.co.in/investor-relations/annual-reports/#annual The schedule of AGM is as set out below: Particulars Details Date and Time of AGM Friday, September 18, 2026 at 10.30 AM (IST). Eligible to vote – Cut-off date Friday, September 11, 2026 Remote e-voting start date and time Tuesday, September 15, 2026; 9.00 AM (IST) Remote e-voting end date and time Thursday, September 17, 2026; 5.00 PM (IST) Website of CDSL for remote e-voting and https://www.evotingindia.com/ or participation in the AGM https://eservices.nsdl.com Kindly take the above information on records. Thanking You, Yours Faithfully, For Solara Active Pharma Sciences Limited Pooja Jaya Kumar Company Secretary & Compliance Officer ICSI Membership No.: A57415 Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636 Registered Office: Cyber One, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703; Tel: +91-22-20870033 FINISHING STRONG, BUILDING FOR GROWTH Solara Active Pharma Sciences Limited Annual Report 2025-26 CONTENTS HIGHLIGHTS OF FY2025-26 02-31 Financial World of Solara 02 Prelude OVERALL 04 About Us 1,375.14 06 Our Business ₹ Crores 10 Manufacturing 14 Cost Optimisation Revenue 16 Research & Development 7% 18 Message from MD & CEO 20 Key Performance Indicators 665.86 22 Environment ₹ Crores 24 People Gross profit (after S&D cost) 26 Community 28 Governance 3% 30 Board of Directors 31 Leadership Team 191.54 ₹ Crores 32-110 EBITDA Statutory Reports 32 Management Discussion and Analysis Environment 39 Board’s Report 62 Corporate Governance Report 83 Business Responsibility and ENERGY Sustainability Report 69.9 111-238 Kilo joules per rupee of turnover in Financial Statements FY2025-26 111 Standalone 176 Consolidated Social 239-253 0.76 ₹ Crores AGM Notice Investment in CSR activities YoY Growth/De-growth BASE BUSINESS* IBUPROFEN BUSINESS^ 1,041.40 333.74 ₹ Crores ₹ Crores Revenue Revenue 6% 9% 573.20 92.66 ₹ Crores ₹ Crores Gross profit (after S&D cost) Gross profit (after S&D cost) 6% 12% 244.50 (52.96) ₹ Crores ₹ Crores EBITDA EBITDA 0.25% 76% *Base business is excluding the commodity ibuprofen business ^Ibuprofen business represents only the commodity ibuprofen business SCOPE 1 & 2 GHG EMISSIONS WATER 27.15 27.7 Metric tonnes of CO₂ per crore of Milliliters per rupee of turnover FY2025-26 turnover in FY2025-26 Governance Independent Directors on the Board, including one Woman Director Prelude The global pharmaceutical increasingly seek partners industry continues to who can consistently undergo significant deliver quality, reliability, transformation, driven by compliance, and rising healthcare needs, innovation. In this evolving regulatory dynamic environment, standards, geopolitical API manufacturers shifts in supply chains, with strong regulatory and rapid technological credentials, diversified advancement. As innovation capabilities, and in chemical synthesis, operational excellence are process development, and becoming indispensable biotechnology reshapes contributors to the global the pharmaceutical healthcare value chain. ecosystem, customers FINISHING STRONG, BUILDING FOR GROWTH 2 Solara Active Pharma Sciences Limited At Solara Active Pharma Sciences focus, and operational agility, we The fundamentals of our business Limited, we remain well positioned delivered a resilient performance remain strong. A robust regulatory to strengthen our role as a and concluded the year on a track record, deep customer preferred global API partner. Our stronger footing. relationships, global market focused API business model, access, and a commitment to diversified product portfolio, Our performance reflects continuous improvement provide established presence across not only the strength of our a solid foundation for the future. regulated markets, and globally business fundamentals but As the pharmaceutical industry compliant manufacturing network also the commitment of our continues to evolve, we believe provide a strong platform to serve employees, the confidence of our Solara is well positioned to capture the evolving needs of customers customers, and the support of our emerging opportunities, create worldwide. Backed by advanced stakeholders. Their trust continues sustainable value, and contribute process capabilities, multipurpose to be a key driver of our progress. meaningfully to improving global manufacturing assets, and a healthcare outcomes. culture rooted in quality and As we look ahead, our priorities compliance, we continue to remain clear. We are focused on With a sharper strategic focus support our customers across a strengthening our technological and a renewed commitment to broad range of complex and high- capabilities, expanding our execution excellence, we enter value pharmaceutical products. development portfolio, and the new year with confidence, enhancing manufacturing determination, and optimism FY2025-26 was a year that tested excellence to improve about the opportunities that the resilience of the industry, yet competitiveness and accelerate lie ahead. also underscored the strength of growth. Investments in advanced our operating model. While pricing chemistry, process engineering, Finishing strong has pressures and continued weakness analytical sciences, and specialised strengthened our in the commodity Ibuprofen manufacturing platforms are foundation. Building segment persisted, the steady enabling us to develop and growth of our core API business commercialise increasingly for growth will define enabled us to navigate these complex molecules with greater our future. challenges effectively. Through efficiency, scalability, and reliability. disciplined execution, customer Key facts 6 ~1,700 75 Manufacturing facilities Employees driving Of revenues from and 1 R&D centre execution Regulated Markets 60 60 3 Countries with active Commercial Successful USFDA global presence products audits across different sites in FY2025-26 Scientists advancing innovation and product development. World Solara Statutory Reports Financial Statements Annual Report 2025-26 3 About Us STRENGTHENING OUR PROMINENCE IN COMMERCIAL APIS Solara Active Pharma Sciences Limited (“Solara”, “the Company”, “we”, “our”, or “us”) has established itself as a leading global manufacturer of commercial Active Pharmaceutical Ingredients (APIs), serving pharmaceutical customers across more than 60 countries. With a diversified product portfolio, deep process expertise, and a strong presence in regulated markets, we are well positioned to support the evolving needs of the global pharmaceutical industry. [Showing first 8,000 characters — download PDF for full document]